first
part
review
ekin
et
al
briefli
describ
histori
develop
field
global
refer
silico
pharmacolog
includ
develop
method
databas
quantit
relationship
qsar
similar
search
pharmacophor
homolog
model
molecular
model
machin
learn
data
mine
network
analysi
data
analysi
tool
use
comput
also
previous
introduc
method
use
virtual
ligand
targetbas
screen
virtual
affin
profil
second
part
review
greatli
expand
applic
method
mani
differ
target
protein
complex
properti
discuss
pharmacolog
space
cover
silico
effort
process
detail
success
silico
method
identifi
new
pharmacolog
activ
molecul
mani
target
highlight
result
enrich
factor
screen
activ
druglik
databas
final
discuss
advantag
disadvantag
silico
method
respect
vitro
vivo
method
pharmacolog
research
enzym
ubiquitin
regulatori
pathway
ubiquitin
conjug
deconjug
substrat
protein
repres
sourc
mani
potenti
target
modul
cancer
diseas
wong
et
al
recent
crystal
structur
mammalian
deubiquitin
enzym
hausp
specif
deubiquitin
ubiquitin
protein
may
also
assist
drug
develop
despit
peptid
natur
substrat
hu
et
al
novel
nonpeptid
inhibitor
proteas
ubiquitin
isopeptidas
deubiquitin
gener
ubiquitin
protein
well
discov
recent
use
simpl
pharmacophorebas
search
nation
cancer
institut
nci
databas
mullal
et
al
mullal
fitzpatrick
inhibitor
valu
low
micromolar
rang
caus
cell
death
independ
tumour
suppressor
mutat
greater
cancer
henc
inhibit
per
se
may
repres
optim
target
modul
ubiquitin
isopeptidas
inhibitor
shikoccin
dibenzylideneaceton
curcumin
recent
describ
punaglandin
coral
indic
steric
access
keton
essenti
bioactiv
verbitski
et
al
molecul
repres
valuabl
lead
chemic
optim
aromatas
cytochrom
cyp
valid
target
breast
cancer
ligandbas
pharmacophor
gener
three
nonsteroid
inhibitor
model
could
recogn
known
inhibitor
inhous
librari
refin
addit
molecular
shape
model
use
search
nci
databas
molecul
score
quantit
catalyst
hyporefin
accelri
inc
san
diego
ca
usa
model
gener
molecul
hit
also
filter
pharmacophor
toxicityrel
protein
test
two
three
compound
ultim
found
micromolar
inhibitor
schuster
et
al
structurebas
catalyst
pharmacophor
develop
acetylcholin
esteras
subsequ
use
search
natur
product
databas
strategi
identifi
scopoletin
scopolin
hit
later
shown
moder
vivo
activ
rolling
et
al
databas
also
screen
cyclooxygenas
cox
structurebas
pharmacophor
lead
identif
known
cox
inhibitor
repres
exampl
combin
ethnopharmacolog
comput
approach
may
aid
drug
discoveri
rolling
et
al
combin
ligandbas
structurebas
approach
taken
gain
structur
insight
human
lox
catalyst
qualit
hiphop
model
creat
differ
molecul
result
fivefeatur
pharmacophor
homolog
model
enzym
base
two
soybean
lox
enzym
one
rabbit
lox
enzym
molecular
dock
use
updat
refin
pharmacophor
fourfeatur
model
could
also
visual
homolog
model
result
model
aminoacid
residu
bind
site
suggest
target
sitedirect
mutagenesi
virtual
screen
pharmacophor
suggest
compound
phenylthiourea
group
test
charlier
et
al
homolog
model
human
also
use
flexibl
ligand
dock
programm
glide
inc
perform
virtual
screen
compound
compound
test
inhibitori
activ
sever
low
micromolar
rang
kenyon
et
al
year
research
renin
enough
deliv
market
drug
inhibit
enzym
spite
renin
remain
attract
yet
elus
target
hypertens
fisher
hollenberg
stanton
respect
applic
structurebas
design
lead
identif
new
nonpeptid
inhibitor
human
renin
molecul
includ
aliskiren
rahuel
et
al
torr
et
al
piperidin
includ
guller
et
al
oefner
et
al
vieira
et
al
relat
piperidin
marki
et
al
interestingli
piperidin
bind
stabil
differ
conform
protein
term
open
renin
bursavich
rich
wherea
aliskiren
bind
close
renin
sinc
latter
structurebas
design
effort
remark
publish
attempt
computeraid
design
novel
renin
inhibitor
singl
earli
qsar
deriv
seri
chainmodifi
peptid
analogu
angiotensinogen
activ
molecul
found
correl
kier
firstord
molecular
connect
index
descriptor
molecular
weight
lipophil
measur
logp
khadikar
et
al
anoth
comput
method
renin
drug
discoveri
use
de
novo
design
softwar
growmol
could
appar
regener
piperidin
grown
structur
bursavich
rich
attempt
use
catalyst
pharmacophor
discov
new
renin
inhibitor
describ
earli
van
drie
sever
novel
molecul
pomona
databas
earli
threedimension
molecul
databas
found
map
renin
pharmacophor
appar
test
vitro
recent
ligandfit
dock
studi
crystal
structur
open
renin
form
abl
detect
known
inhibitor
seed
librari
compound
within
top
use
consensu
score
function
four
exampl
highscor
compound
test
inhibitor
fulfil
pharmacophor
deriv
xray
data
consist
four
hydrophob
hydrogen
bond
donor
posit
ioniz
featur
well
exclud
volum
krovat
langer
anoth
studi
use
similar
search
mddr
databas
compound
use
renin
inhibitor
abl
produc
enrich
factor
greater
random
hert
et
al
genet
algorithm
also
use
class
discrimin
renin
inhibitor
noninhibitor
subset
mddr
use
small
number
interpret
descriptor
among
amid
bond
count
molecular
weight
hydrogen
bond
donor
count
found
much
higher
renin
inhibitor
ganguli
et
al
recent
public
novel
renin
inhibitor
repres
consider
amount
new
inform
could
use
qsar
model
develop
databas
search
effort
order
deriv
novel
start
scaffold
optim
cathepsin
aspart
proteas
found
mainli
lysosom
may
role
precursor
protein
releas
henc
may
well
target
alzheim
diseas
cathepsin
may
also
elev
breast
cancer
ovarian
cancer
henc
mean
modul
activ
could
benefici
diseas
brief
overview
cathepsin
comprehens
review
proteas
inhibitor
leung
et
al
combin
structurebas
design
algorithm
combinatori
chemistri
success
appli
find
novel
molecul
cathepsin
nanomolar
rang
kick
et
al
structur
base
pepstatin
pm
inhibitor
baldwin
et
al
yield
hit
rate
molecul
test
vitro
use
hippocamp
slice
shown
block
format
hyperphosphoryl
tau
fragment
bi
et
al
rel
comput
studi
date
cathepsin
relat
aspart
proteas
renin
one
studi
use
molecular
dynam
free
energi
analys
mmpbsa
cathepsin
inhibitor
interact
suggest
new
substitut
may
improv
bind
huo
et
al
genet
algorithmbas
de
novo
design
tool
adapt
also
use
rediscov
activ
cathepsin
molecul
place
key
fragment
correct
posit
pegg
et
al
comput
model
may
aid
select
novel
ligand
proteas
inhibit
nonpeptid
select
use
structur
featur
eight
publish
inhibitor
cathepsin
huo
et
al
fivefeatur
pharmacophor
deriv
consist
three
hydrophob
two
hydrogen
bond
acceptor
pharmacophor
use
search
molecul
databas
select
molecul
present
contrast
similar
search
level
use
chemfind
cambridgesoft
cambridg
usa
suggest
differ
molecul
select
test
vitro
pharmacophor
produc
four
hit
hit
rate
similar
search
gener
five
hit
hit
rate
least
one
replic
show
greater
inhibit
ekin
et
al
silico
evalu
adm
properti
activ
compound
estim
molecul
would
well
absorb
although
predict
solubl
inhibit
problem
pharmacophor
structurebas
approach
use
optim
acyl
urea
hit
human
glycogen
phosphorylas
catalyst
hypogen
fivefeatur
pharmacophor
develop
use
guid
analogu
synthesi
compound
show
good
correl
predict
xray
structur
one
molecul
use
confirm
predict
bind
conform
ultim
compar
molecular
field
analysi
comfa
model
gener
molecul
synthes
found
complementari
xray
structur
outcom
studi
molecul
good
cellular
activ
could
inhibit
blood
glucos
level
vivo
rat
klabund
et
al
human
sirtuin
type
target
control
age
cancer
deacetyl
crystal
high
resolut
structur
use
dock
maybridg
databas
return
small
hit
list
compound
test
show
activ
micromolar
level
tervo
et
al
catechol
omethyltransferas
target
parkinson
diseas
current
crystal
structur
enzym
use
gener
homolog
model
human
enzym
model
use
dock
flexx
softwar
sever
catechin
tea
understand
structureact
relationship
sar
molecul
metabolit
test
vitro
ultim
combin
vitro
comput
work
indic
galloyl
group
catechin
distanc
ly
enzym
react
catechol
hydroxi
group
import
inhibit
chen
et
al
kinas
repres
attract
famili
target
pharmaceut
industri
sever
drug
approv
recent
kinas
space
map
use
select
data
small
molecul
creat
chemogenom
dendrogram
kinas
show
highli
homolog
kinas
inhibit
similarli
small
molecul
vieth
et
al
virtual
screen
method
appli
quit
wide
kinas
date
fischer
structurebas
design
method
produc
new
potent
inhibitor
start
highli
similar
apo
posit
olomoucin
aminoacid
residu
mutat
conform
sequenc
macromodel
use
energi
minim
molecul
atp
pocket
visual
inspect
suggest
point
molecular
modif
ligand
quickli
design
effort
guid
ligand
optim
improv
activ
nm
furet
et
al
recent
b
homolog
model
also
use
manual
dock
ligand
enabl
progress
alsterpaullon
nm
deriv
nm
kunick
et
al
structurebas
silico
screen
method
pursu
syk
ctermin
domain
use
dock
find
low
molecular
weight
fragment
bind
site
millimolar
bind
affin
fragment
link
result
molecul
rang
start
point
lead
optim
niimi
et
al
pseudoreceptor
model
built
set
epiderm
growth
factor
receptor
egfr
tyrosin
kinas
inhibitor
flexibl
atom
receptor
model
method
top
model
creat
high
also
valid
sixmolecul
test
set
pseudoreceptor
also
accord
crystal
structur
peng
et
al
virtual
screen
use
dock
crystal
structur
lck
domain
use
screen
two
million
commerci
avail
molecul
extens
filter
requir
result
manag
hit
list
use
molecular
weight
divers
compound
test
vitro
inhibitori
activ
fluoresc
titrat
compound
suggest
kd
valu
low
micromolar
rang
huang
et
al
group
also
took
similar
approach
discov
inhibitor
screen
compound
comput
test
vitro
hancock
et
al
five
molecul
inhibit
cell
prolifer
two
shown
fluoresc
titrat
bind
kd
valu
low
micromolar
rang
case
dock
activ
molecul
suggest
orient
verif
xray
crystallographi
hancock
et
al
ligand
scout
method
use
bcrabl
tyrosin
kinas
find
imatinib
gleevec
singl
multipl
conform
databas
wolber
langer
structur
relat
threesubstitut
benzamidin
deriv
suggest
structurebas
design
manual
dock
bind
site
energi
minim
shown
form
favour
interact
hydrophob
pocket
pkd
part
signalosom
control
stabil
cjun
import
tumour
develop
curcumin
besid
inhibitor
ubiquitin
isopeptidas
mullal
et
al
mullal
fitzpatrick
activ
tsuchida
et
al
also
inhibit
pkd
use
curcumin
emodin
refer
structur
databas
million
molecul
screen
mean
similar
search
retriev
molecul
among
seven
possess
inhibitori
activ
exampl
piceatannol
potent
curcumin
pkd
valu
respect
fullbeck
et
al
obvious
exampl
suggest
success
find
activ
molecul
kinas
interestingli
studi
select
toward
kinas
account
ultim
therapeut
success
activ
toward
sever
kinas
select
toward
other
may
requir
mathemat
model
describ
quantit
relationship
pioneer
hansch
et
al
use
small
set
similar
molecul
molecular
descriptor
later
lewi
cowork
provid
mani
qsar
homolog
model
individu
human
cyp
lewi
sophist
comput
model
tool
becam
avail
seen
growth
number
avail
model
de
groot
ekin
de
graaf
et
al
de
groot
size
data
set
encompass
recent
method
also
incorpor
water
molecul
bind
site
dock
molecul
enzym
may
import
hydrogen
bond
mediat
bind
site
amino
acid
lill
et
al
dock
method
also
use
suggest
novel
metabolit
drug
recent
exampl
use
homolog
model
dock
metoclopramid
well
drug
show
good
correl
dock
score
yu
et
al
novel
aromat
nhydroxi
metabolit
suggest
major
metabolit
confirm
vitro
sever
crystal
structur
mammalian
cyp
avail
found
compar
quit
favour
prior
comput
model
rowland
et
al
howev
enzym
like
ligand
protein
promiscu
may
difficulti
make
reliabl
predict
comput
approach
dock
avail
crystal
structur
ekroo
sjogren
henc
multipl
pharmacophor
model
may
necessari
enzym
ekin
et
al
indic
other
recent
mao
et
al
udpglucuronosyltransferas
class
versatil
enzym
involv
elimin
drug
catalys
conjug
glucuron
acid
substrat
bear
suitabl
function
group
call
phase
ii
enzym
numer
qsar
pharmacophor
model
gener
rel
small
data
set
rat
human
enzym
pharmacophor
human
common
two
hydrophob
glucuronid
featur
addit
hydrogen
bond
acceptor
featur
smith
et
al
sorich
et
al
sulfotransferas
second
class
conjug
enzym
crystal
dajani
et
al
gamag
et
al
qsar
method
also
use
predict
substrat
affin
dajani
et
al
best
knowledg
comput
model
isozym
develop
gener
conjug
enzym
gener
infrequ
target
silico
model
perhap
pauciti
vitro
data
limit
divers
molecul
test
less
wide
appli
industri
comput
model
drug
transport
thoroughli
review
numer
group
zhang
et
al
chang
swaan
address
detail
variou
transport
model
also
appli
databas
search
discov
substrat
inhibitor
langer
et
al
pleban
et
al
chang
et
al
increas
effici
vitro
screen
chang
et
al
enrich
random
screen
pharmacophor
model
nadglucos
cotransport
found
renal
proxim
tubul
deriv
indirectli
use
phlorizin
analogu
disco
programm
superpos
molecul
enabl
estim
size
bind
site
obtain
contrast
recent
studi
transport
pharmacophor
model
test
use
databas
search
wielertbadt
et
al
differ
famili
receptor
present
plasma
membran
altogeth
repres
protein
receptorom
strachan
et
al
receptor
wide
use
drug
target
wide
array
potenti
ligand
howev
note
date
character
found
agonist
antagonist
small
percentag
receptorom
propion
receptor
central
mani
central
nervou
system
cn
patholog
ligand
synthes
anticonvuls
neuroprotect
current
structur
inform
therefor
fourpoint
catalyst
hiphop
pharmacophor
develop
antagonist
use
search
maybridg
databas
select
eight
compound
test
six
found
activ
vivo
anticonvuls
barreca
et
al
serotonin
play
role
mani
physiolog
system
cn
intestin
wall
along
mani
receptor
major
development
function
regul
cardiovascular
morphogenesi
receptor
famili
g
proteincoupl
span
receptor
express
cardiovascular
gut
brain
tissu
well
human
carcinoid
tumor
nebigil
et
al
recent
year
receptor
implic
valvular
heart
diseas
defect
caus
ban
fenphen
treatment
patient
primari
metabolit
norfenfluramin
potent
stimul
fitzgerald
et
al
rothman
et
al
comput
model
receptor
limit
date
tradit
qsar
studi
use
small
number
deriv
antagonist
rat
contractil
receptor
rat
stomach
fundu
singh
kumar
gridgolp
use
aminoalkyl
benzo
heterocycloalkanon
antagonist
human
receptor
result
poor
model
statist
possibl
owe
limit
rang
activ
measur
fact
data
correspond
function
respons
like
complex
brea
et
al
neither
model
valid
extern
predict
basi
bacteriorhodopsin
rhodopsin
homolog
model
mous
human
receptor
combin
sitedirect
mutagenesi
bacteriorhodopsin
structur
provid
reliabl
model
confirm
aromat
box
hypothesi
ligand
interact
along
transmembran
domain
serotonin
manivet
et
al
recent
homolog
model
base
rhodopsinbas
model
rat
use
determin
site
interact
norfenfluramin
follow
molecular
dynam
simul
sitedirect
mutagenesi
show
val
implic
highaffin
bind
van
der
waal
interact
ligand
methyl
group
setola
et
al
certainli
opportun
develop
qsar
model
receptor
order
rapidli
screen
librari
molecul
identifi
undesir
potent
inhibitor
serotonin
receptor
frequent
model
exampl
conform
studi
four
ligand
defin
pharmacophor
antagonist
site
use
sybyl
hibert
et
al
model
result
activ
analogu
approach
use
molecul
design
predict
molecul
stereospecif
recent
seri
homolog
model
iter
creat
base
crystal
structur
bovin
rhodopsin
turn
tune
flexx
dock
known
ligand
final
model
use
virtual
screen
simul
enrich
inhibitor
compar
random
select
author
suggest
util
real
virtual
screen
nowak
et
al
homolog
model
receptor
also
use
dock
screen
librari
compound
seed
ligand
nineti
percent
activ
compound
rank
top
compound
becker
et
al
repres
signific
enrich
model
use
screen
librari
vendor
compound
select
test
activ
one
possess
nm
affin
structurebas
silico
optim
perform
improv
select
gpcr
optim
pharmacokinet
pk
profil
howev
proceed
molecul
found
affin
human
ether
agogorel
gene
herg
subsequ
comput
assess
use
homolog
model
point
adjust
hydrophob
result
clinic
candid
good
target
antitarget
select
backup
compound
select
way
becker
et
al
anoth
earli
computeraid
pharmacophor
gener
sybyl
use
set
select
nonselect
analogu
use
design
agonist
antimigrain
agent
select
link
undesir
chang
blood
pressur
glen
et
al
rang
typic
atyp
antipsychot
bind
receptor
base
structur
bovin
rhodopsin
homolog
model
human
rodent
receptor
construct
use
dock
ligand
known
exhibit
speci
differ
bind
hirst
et
al
follow
sequenc
align
aminoacid
residu
identifi
mutat
ration
mutat
effect
ligand
bind
obtain
dock
studi
model
gener
good
agreement
vitro
data
could
use
molecul
design
studi
good
exampl
comput
molecular
biolog
tradit
pharmacolog
method
combin
hirst
et
al
na
katpas
receptor
cardioton
steroid
turn
inhibit
atpas
cation
transport
ionotrop
action
although
effect
digitali
known
hundr
year
molecular
understand
remain
absent
recent
homolog
model
gener
crystal
structur
test
nine
cardiac
glycosid
keenan
et
al
model
also
mutat
mimic
rat
receptor
show
oubain
would
orient
differ
model
perhap
explain
speci
differ
affin
model
also
suggest
amino
acid
could
experiment
mutat
valid
hypothesi
bind
site
identif
although
yet
test
dopamin
receptor
implic
parkinson
diseas
schizophrenia
unfortun
crystal
structur
current
avail
thu
search
new
antagonist
use
qsar
model
set
compound
use
four
differ
qsar
method
comfa
simul
annealingparti
least
squar
pl
knearest
neighbour
knn
svm
train
well
test
statist
gener
svm
knn
model
also
use
mine
compound
databas
molecul
result
consensu
hit
five
hit
known
bind
receptor
train
set
suggest
hit
contain
catechol
group
normal
seen
dopamin
inhibitor
oloff
et
al
receptor
target
control
vascular
tone
therefor
use
antihypertens
agent
novel
approach
ligandbas
screen
call
multipl
featur
tree
mtree
describ
train
set
molecul
featur
tree
descriptor
deriv
topolog
molecular
graph
align
pairwis
fashion
hessler
et
al
set
six
antagonist
use
deriv
model
method
compar
catalyst
pharmacophor
model
approach
identifi
central
posit
ioniz
featur
flank
hydrophob
region
either
end
two
method
compar
abil
rank
databas
molecul
within
top
databas
mtree
enrich
factor
twice
obtain
catalyst
hessler
et
al
nuclear
receptor
constitut
famili
ligandactiv
transcript
factor
paramount
import
pharmaceut
industri
sinc
mani
member
often
consid
doubleedg
sword
shi
one
hand
import
regulatori
role
varieti
biolog
process
mutat
nuclear
receptor
associ
mani
common
human
diseas
cancer
diabet
osteoporosi
thu
also
consid
highli
relev
therapeut
target
hand
nuclear
receptor
act
also
regul
cyp
enzym
respons
metabol
pharmaceut
relev
molecul
well
transport
mediat
drug
efflux
thu
also
regard
potenti
therapeut
antitarget
offtarget
exampl
use
targetbas
virtual
screen
identifi
novel
small
molecul
modul
nuclear
receptor
recent
report
use
avail
structur
oestrogen
receptor
subtyp
antagonist
conform
homolog
model
retino
acid
receptor
construct
schapira
et
al
use
homolog
model
virtual
screen
compound
librari
lead
identif
two
novel
antagonist
micromolar
rang
approach
later
appli
discov
novel
divers
micromolar
antagonist
thyroid
hormon
receptor
schapira
et
al
mean
procedur
design
particularli
select
compound
fit
onto
lxxll
peptidebind
surfac
oestrogen
receptor
novel
antagonist
identifi
shao
et
al
sinc
poor
displac
observ
erligand
competit
assay
compound
may
repres
new
class
antagonist
potenti
provid
altern
current
antioestrogen
therapi
discoveri
three
low
micromolar
hit
display
bind
select
respect
also
recent
report
use
databas
screen
zhao
brinton
final
exampl
report
identif
optim
novel
famili
peroxisom
proliferatoractiv
partial
agonist
base
upon
employ
structurebas
virtual
screen
good
select
profil
subtyp
nuclear
receptor
group
lu
et
al
therapeut
import
channel
includ
voltageg
ion
channel
potassium
sodium
calcium
present
outer
membran
mani
differ
cell
respons
electr
excit
signal
nerv
muscl
cell
terlau
stuhmer
repres
valid
therapeut
target
anaesthesia
cn
cardiovascular
diseas
kang
et
al
recent
review
discuss
variou
qsar
method
pharmacophor
comfa
svm
genet
program
self
organ
map
recurs
partit
appli
ion
channel
aronov
et
al
absenc
crystal
structur
date
ltype
calcium
channel
herg
appear
extens
studi
channel
regard
contrast
far
fewer
exampl
comput
model
sodium
channel
three
class
ion
channel
studi
repres
either
therapeut
target
antitarget
avoid
exampl
one
mani
model
herg
potassium
channel
compar
three
differ
method
set
molecul
train
test
set
recurs
partit
sammon
map
kohonen
map
use
atom
path
length
ekin
et
al
averag
classif
qualiti
high
train
test
select
sammon
map
techniqu
outperform
kohonen
map
classif
compound
extern
test
set
quantit
predict
recurs
partit
could
filter
use
tanimoto
similar
remov
molecul
markedli
differ
train
set
willett
path
length
descriptor
also
use
visual
similar
molecul
whole
train
set
figur
addit
subset
molecul
also
compar
highlight
blue
repres
close
neighbour
red
distant
figur
cyclic
decapeptid
activ
transcript
factor
use
deriv
pharmacophor
low
energi
conform
nonpeptid
compound
compar
new
decan
benzophenon
deriv
activ
bind
cellbas
assay
discov
inhibitor
lead
hop
approach
tsuchida
et
al
twenti
deoxythymidin
monophosph
analogu
use
along
dock
gener
pharmacophor
mycobacterium
tuberculosi
thymidin
monophosphosph
kinas
inhibitor
catalyst
softwar
final
model
use
screen
larg
databas
spike
known
inhibitor
model
suggest
enrich
factor
highli
signific
addit
model
use
rapidli
screen
half
million
compound
effort
discov
new
inhibitor
gopalakrishnan
et
al
neuroamidas
major
surfac
protein
influenza
viru
structurebas
approach
use
gener
catalyst
pharmacophor
turn
use
databas
search
aid
discoveri
known
inhibitor
hit
list
also
select
steindl
langer
human
rhinoviru
proteas
antirhin
target
structurebas
pharmacophor
develop
initi
around
ag
prove
restrict
second
pharmacophor
develop
seven
peptid
inhibitor
use
catalyst
hiphop
method
hypothesi
use
search
world
drug
index
databas
retriev
compound
known
antivir
activ
sever
novel
compound
select
databas
good
fit
pharmacophor
indic
would
worth
test
although
ultim
test
valid
data
present
steindl
et
al
human
rhinoviru
coat
protein
anoth
target
antirhin
combin
pharmacophor
dock
approach
pcabas
cluster
use
pharmacophor
gener
structur
shape
known
inhibitor
test
abil
find
known
inhibitor
databas
ultim
screen
maybridg
databas
compound
suggest
dock
score
six
compound
test
found
inhibit
viral
growth
howev
major
found
cytotox
poor
solubl
steindl
et
al
ligand
scout
approach
test
rhinoviru
serotyp
abl
find
known
inhibitor
pdb
wolber
langer
sar
coronaviru
proteinas
address
potenti
drug
design
target
homolog
model
built
chemic
databas
dock
pharmacophor
model
druglik
rule
use
narrow
hit
list
forti
compound
test
three
found
micromolar
activ
best
calmidazolium
liu
et
al
perhap
start
point
optim
pharmacophor
also
develop
predict
hepat
c
viru
rnadepend
rna
polymeras
inhibit
diketo
acid
deriv
catalyst
hypogen
model
deriv
molecul
activ
three
log
order
result
fivefeatur
pharmacophor
model
turn
test
compound
data
set
well
nine
diketo
acid
deriv
predict
experiment
data
good
agreement
di
santo
et
al
integrin
target
autoimmun
inflammatori
diseas
asthma
rheumatoid
arthriti
search
antagonist
includ
use
catalyst
pharmacophor
deriv
xray
crystal
structur
peptid
inhibitor
singh
et
al
use
search
virtual
databas
compound
could
made
reagent
avail
chemic
directori
twelv
compound
select
synthes
result
activ
rang
nm
henc
peptid
use
deriv
nonpeptid
inhibitor
activ
vivo
second
studi
group
use
comfa
set
antagonist
activ
nm
gener
model
good
intern
valid
statist
subsequ
use
indic
favour
region
molecul
substitu
chang
singh
et
al
unclear
whether
comfa
model
also
success
design
molecul
possibl
use
approv
drug
start
point
drug
discoveri
diseas
exampl
list
world
health
organ
essenti
drug
search
tri
find
lead
prion
diseas
use
tanimoto
similar
search
known
inhibitor
work
date
suggest
compound
yet
appear
test
approach
complet
valid
lorenzen
et
al
interact
key
compon
cellular
signal
cascad
select
interrupt
would
repres
sought
therapeut
mechan
modul
variou
diseas
tesmer
howev
pharmacolog
target
difficult
silico
method
deriv
small
molecul
inhibitor
owe
gener
quit
shallow
bind
site
gprotein
complex
regul
number
signal
protein
via
interact
search
small
molecul
interfer
interact
target
use
flexx
dock
consensu
score
molecul
nci
divers
set
databas
bonacci
et
al
test
compound
inhibitor
peptid
nine
compound
identifi
valu
nm
substructur
search
use
identifi
similar
compound
one
potent
inhibitor
build
sar
effort
may
eventu
lead
potent
lead
compound
point
gener
consid
silico
pharmacolog
model
essenti
relat
singl
target
protein
either
discoveri
molecul
agonist
antagonist
biolog
activ
databas
search
vitro
test
follow
search
databas
seed
molecul
known
activ
target
howev
mani
complex
properti
model
silico
briefli
discuss
also
point
sever
physicochem
properti
clogp
water
solubl
extens
studi
train
set
model
ten
thousand
molecul
complex
properti
gener
use
much
smaller
train
set
rang
hundr
molecul
exampl
measur
molecul
clearanc
would
indic
elimin
halflif
would
natur
valu
select
candid
intrins
clearanc
therefor
use
measur
enzym
activ
toward
compound
may
involv
multipl
enzym
earliest
model
properti
includ
comfa
model
cypmedi
metabol
chlorin
volatil
organ
compound
like
repres
waller
et
al
gener
set
molecul
clearanc
data
deriv
human
hepatocyt
use
predict
human
vivo
clearanc
use
multipl
linear
regress
pca
pl
neural
network
leaveoneout
crossvalid
schneider
et
al
microsom
hepatocyt
clearanc
data
set
also
use
separ
gener
catalyst
pharmacophor
test
predict
oppos
data
set
method
assum
pharmacophor
featur
intrins
molecul
dictat
intrins
clearanc
ekin
obach
second
complex
properti
volum
distribut
function
extent
drug
partit
tissu
versu
plasma
sever
attempt
model
properti
lombardo
et
al
properti
along
plasma
halflif
determin
appropri
dose
drug
exampl
divers
drug
literatur
use
eight
molecular
descriptor
sammon
kohonen
map
method
model
appear
classifi
correctli
compound
balakin
et
al
recent
set
drug
literatur
volum
distribut
steadyst
data
use
mixtur
discrimin
analysisrandom
forest
method
molecular
descriptor
gener
predict
model
model
test
molecul
result
geometr
mean
fold
error
compar
valu
predict
properti
anim
vitro
method
lombardo
et
al
third
properti
plasma
halflif
determin
numer
adm
properti
also
model
sammon
kohonen
map
use
data
drug
literatur
four
molecular
descriptor
like
previous
describ
volum
distribut
model
model
appear
classifi
correctli
compound
balakin
et
al
fourth
complex
properti
renal
clearanc
assum
excret
unchang
drug
take
place
rout
henc
repres
method
monitor
proport
drug
metabol
one
set
publish
qsar
model
molecul
use
volsurf
molconnz
descriptor
model
test
molecul
one
use
soft
independ
model
class
analog
molconnz
descriptor
obtain
correct
classif
two
class
doddareddi
et
al
fifth
exampl
complex
properti
interact
appropri
score
function
sever
method
develop
forc
field
empir
knowledgebas
approach
see
also
ekin
et
al
import
comput
structurebas
design
method
assess
virtual
candid
molecul
select
like
bind
protein
highest
affin
shimada
recent
kernel
partial
least
squar
kplss
qsar
approach
use
along
genet
algorithm
featur
select
method
distancedepend
atom
pair
descriptor
small
molecul
train
set
bind
affin
data
protein
bind
bootstrap
scrambl
data
extern
test
set
use
test
model
deng
et
al
essenc
kpl
qsar
model
across
mani
protein
perhap
isol
key
molecular
descriptor
relat
highest
affin
interact
interest
see
whether
model
continu
gener
much
larger
bind
affin
data
set
avail
final
exampl
complex
properti
vmax
enzym
model
occas
hirashima
et
al
mager
et
al
ghafourian
rashidi
sipila
taskinen
valu
depend
properti
compound
question
influenc
steric
properti
activ
site
well
eas
expuls
leav
group
activ
site
balakin
et
al
recent
use
neural
network
method
model
vmax
data
ndealkyl
mediat
use
whole
molecul
centroid
reaction
leav
grouprel
descriptor
model
also
use
predict
small
set
molecul
includ
train
ultim
mani
reaction
evalu
enzym
necessari
similarli
larger
test
set
requir
complex
properti
model
provid
confid
model
term
util
applic
propos
gener
schema
silico
pharmacolog
shown
figur
demonstr
key
role
comput
technolog
assist
pharmacolog
role
includ
find
new
antagonist
agonist
target
use
array
method
either
absenc
presenc
structur
target
comput
method
may
also
aid
understand
underli
biolog
use
networkpathway
base
annot
data
signal
cascad
determin
connect
drug
network
target
understand
select
integr
model
pkpd
pharmacodynam
ultim
emerg
system
silico
pharmacolog
obvious
taken
pharmaceut
bia
review
would
argu
method
equal
amen
consid
discov
new
chemic
probe
academ
pharmacologist
oppos
lead
molecul
optim
becom
drug
advantag
silico
pharmacolog
silico
method
gener
reduct
number
molecul
made
test
databas
search
find
inhibitor
substrat
increas
speed
experi
reliabl
predict
pharmaceut
properti
molecul
structur
alon
ultim
reduct
anim
reagent
use
must
howev
consid
multipl
optim
numer
predict
properti
possibl
either
weight
silico
pharmacolog
model
import
confid
model
data
well
data
set
size
divers
similarli
consid
disadvantag
silico
pharmacolog
method
protein
flexibl
molecul
conform
promiscu
hinder
accur
predict
exampl
even
recent
avail
crystal
structur
sever
mammalian
drugmetabol
enzym
still
consider
difficulti
reliabl
metabol
predict
focu
thu
far
creation
mani
silico
pharmacolog
model
human
properti
yet
pharmacolog
use
anim
much
vivo
test
subcellular
prepar
sever
speci
vitro
experi
need
model
speci
understand
differ
well
enabl
better
scale
wide
discuss
disadvantag
silico
method
applic
model
discuss
silico
pharmacolog
method
use
similar
limit
model
use
area
predict
physicochem
admetox
properti
exampl
model
may
gener
narrow
homolog
seri
pharmacolog
relev
molecul
local
model
structur
divers
rang
molecul
global
model
two
approach
pro
con
respect
applic
domain
local
model
may
much
narrow
global
model
chang
new
chemic
seri
result
predict
failur
howev
global
model
may
also
fail
predict
molecul
fall
far
enough
away
repres
molecul
train
set
limit
particularli
specif
qsar
model
mani
silico
pharmacolog
model
exampl
describ
qsar
model
gener
local
natur
limit
lead
hop
new
structur
seri
wherea
global
model
may
use
featur
sever
paper
describ
applic
domain
model
method
consider
detail
dimitrov
et
al
tetko
et
al
calcul
properti
molecular
similar
train
set
compound
may
reliabl
measur
predict
qualiti
sheridan
et
al
demonstr
herg
model
ekin
et
al
knowledg
specif
analysi
applic
domain
specif
silico
pharmacolog
model
exampl
describ
degre
physicochem
properti
like
solubl
logp
applic
domain
pharmacophor
model
address
either
focu
primarili
statist
qsar
method
shift
toward
hybrid
metacomput
method
integr
sever
model
approach
algorithm
predict
molecular
structur
possibl
physicochem
pharmacolog
properti
could
use
provid
predict
confid
consensu
dock
method
homolog
model
certain
protein
pharmacolog
interest
could
use
alongsid
qsar
pharmacophor
model
also
avail
numer
occas
studi
drugmetabol
enzym
qsar
homolog
model
combin
use
valid
de
groot
et
al
de
graaf
et
al
de
groot
drug
metabol
good
exampl
sever
simultan
outcom
exampl
metabolit
often
occur
condit
normal
found
pharmacolog
assay
singl
set
condit
yield
singl
outcom
classif
specif
local
comprehens
global
method
find
clearest
use
see
figur
local
method
applic
simpl
biolog
system
singl
enzym
singl
enzymat
activ
testa
product
regioselect
metabolit
exampl
hydroxyl
phenol
alcohol
usual
predict
method
differ
rout
exampl
oxid
versu
glucuronid
global
algorithm
applic
versatil
biolog
system
use
potenti
capac
encompass
metabol
reaction
offer
predict
much
closer
vivo
situat
readili
appar
minor
paper
found
comput
approach
result
predict
lead
compound
test
without
author
provid
experiment
verif
biolog
activ
krovat
langer
langer
et
al
steindl
langer
gopalakrishnan
et
al
lorenzen
et
al
steindl
et
al
amin
welsh
interest
observ
mani
year
comput
studi
gener
perform
synthesi
molecul
essenti
provid
illustr
pictur
explan
data
appear
see
shift
direct
predict
publish
pharmacolog
activ
without
appar
requir
vitro
vivo
experiment
verif
long
model
valid
manner
model
may
limit
predict
domain
perhap
futur
see
discuss
predict
molecul
distanc
train
set
measur
far
predict
extend
mani
molecul
identifi
virtual
screen
techniqu
test
vitro
ensur
fals
posit
may
actual
involv
molecul
aggreg
type
molecul
term
socal
promiscu
inhibitor
occur
micromolar
inhibitor
sever
protein
mcgovern
et
al
mcgovern
shoichet
seidler
et
al
preliminari
comput
model
develop
help
identifi
potenti
promiscu
inhibitor
seidler
et
al
review
literatur
suggest
would
worth
research
either
implement
filter
promiscu
inhibitor
perform
rigor
experiment
verif
predict
bioactiv
molecul
rule
possibl
public
bia
perhap
also
limit
number
exampl
failur
comput
method
publish
would
certainli
use
know
exist
difficult
target
model
differ
method
appar
process
trial
error
investig
current
summari
accompani
review
ekin
et
al
present
interpret
silico
pharmacolog
describ
field
develop
far
use
discoveri
molecul
bind
mani
differ
target
display
bioactiv
predict
complex
properti
understand
underli
metabol
network
interact
explicitli
discuss
pkpd
whole
organ
cell
diseas
simul
review
recogn
import
compon
computeraid
drug
design
approach
nobl
colatski
gomeni
et
al
kansal
may
wide
integr
silico
pharmacolog
method
describ
previous
ekin
et
al
brief
histori
silico
pharmacolog
taken
perhap
rather
predict
rout
comput
model
appli
mani
import
biolog
target
capac
use
search
larg
databas
quickli
suggest
molecul
test
mani
exampl
present
demonstr
signific
enrich
random
select
molecul
far
plenti
type
metric
routin
use
valid
silico
model
futur
silico
pharmacolog
may
somewhat
difficult
predict
see
closer
interact
comput
vitro
approach
date
see
similar
relationship
vivo
studi
futur
broadli
silico
pharmacolog
ever
abl
replac
entir
experiment
approach
vitro
even
vivo
anim
right
activist
want
us
believ
answer
clear
resound
least
near
futur
two
irrefut
reason
first
biolog
entiti
nonlinear
system
show
chaotic
behaviour
relat
magnitud
input
magnitud
output
even
minuscul
differ
initi
condit
rapidli
translat
major
differ
output
second
comput
programm
howev
complex
systemslik
ever
abl
fulli
model
complex
biolog
system
inde
formul
mathematician
gregori
chaitin
biolog
system
algorithm
incompress
mean
model
fulli
algorithm
shorter
meantim
silico
pharmacolog
like
becom
complex
requir
degre
integr
model
see
combin
metabol
model
approach
figur
ultim
much
broader
impact
silico
tool
need
becom
part
everi
pharmacologist
tool
kit
requir
train
model
informat
alongsid
vivo
vitro
molecular
skill
provid
realist
appreci
differ
silico
method
expect
regard
pharmacologist
aim
discov
new
therapeut
